Inhibrx Biosciences, Inc.
INBXNASDAQHealthcare● Active
$87.94
+$0.93(+1.07%)
Market Cap$1.3B
P/E Ratio—
52W High$155.29
52W Low$12.8
Inhibrx Biosciences, Inc. (INBX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INBX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$2.15
Est. -$2.37 · +9.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
INBX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$2.28 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$2.37 | -$2.15 | +9.3% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$2.08 | -$2.11 | -1.4% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$2.08 | -$2.28 | -9.6% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$2.92 | -$1.85 | +36.6% | $0.00B | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$2.55 | -$2.80 | -9.8% | — | — | — |
| ▼ Q1 FY2025 | Mar 17, 2025 | -$2.88 | -$3.09 | -7.3% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$3.06 | -$2.84 | +7.2% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$2.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$2.15
EPS Est.
-$2.37
EPS Surpr.
+9.3%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$2.11
EPS Est.
-$2.08
EPS Surpr.
-1.4%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$2.28
EPS Est.
-$2.08
EPS Surpr.
-9.6%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$1.85
EPS Est.
-$2.92
EPS Surpr.
+36.6%
Revenue
$0.00B
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$2.80
EPS Est.
-$2.55
EPS Surpr.
-9.8%
Revenue
—
Q1 FY2025
Mar 17, 2025Miss
EPS Actual
-$3.09
EPS Est.
-$2.88
EPS Surpr.
-7.3%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$2.84
EPS Est.
-$3.06
EPS Surpr.
+7.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.22 | $-1.22 | $-1.22 | 1 |
| Q3 FY2027 | $-1.39 | $-1.39 | $-1.39 | 1 |
| Q2 FY2027 | $-1.86 | $-1.86 | $-1.86 | 1 |
| Q1 FY2027 | $-1.83 | $-1.83 | $-1.83 | 1 |
| Q4 FY2026 | $-2.50 | $-2.50 | $-2.50 | 1 |
| Q3 FY2026 | $-2.43 | $-2.43 | $-2.43 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +9.3% | $117.95 | $116.16 | -1.52% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -1.4% | $68.69 | $64.87 | -5.56% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -9.6% | $74.62 | $79.13 | +6.04% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +36.6% | $21.92 | $23.57 | +7.53% |
| ▼ Q2 FY2025 | May 14, 2025 | -9.8% | $11.28 | $10.84 | -3.90% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -7.3% | $14.10 | $13.94 | -1.13% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +7.2% | $15.45 | $14.33 | -7.25% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +3585.6% | $11.25 | $11.30 | +0.44% |
Q2 FY2026-1.52%
Report Date
May 14, 2026
EPS Beat/Miss
+9.3%
Price Before
$117.95
Price After
$116.16
Q1 FY2026-5.56%
Report Date
Mar 19, 2026
EPS Beat/Miss
-1.4%
Price Before
$68.69
Price After
$64.87
Q4 FY2025+6.04%
Report Date
Nov 14, 2025
EPS Beat/Miss
-9.6%
Price Before
$74.62
Price After
$79.13
Q3 FY2025+7.53%
Report Date
Aug 13, 2025
EPS Beat/Miss
+36.6%
Price Before
$21.92
Price After
$23.57
Q2 FY2025-3.90%
Report Date
May 14, 2025
EPS Beat/Miss
-9.8%
Price Before
$11.28
Price After
$10.84
Q1 FY2025-1.13%
Report Date
Mar 17, 2025
EPS Beat/Miss
-7.3%
Price Before
$14.10
Price After
$13.94
Q4 FY2024-7.25%
Report Date
Nov 14, 2024
EPS Beat/Miss
+7.2%
Price Before
$15.45
Price After
$14.33
Q3 FY2024+0.44%
Report Date
Aug 13, 2024
EPS Beat/Miss
+3585.6%
Price Before
$11.25
Price After
$11.30
Avg Beat Reaction-0.20%
Avg Miss Reaction-1.14%
Beat Rate4 / 8 quarters
Largest Move+7.53% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INBX ends December
Inhibrx Biosciences, Inc. (INBX) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-2.15 — beating the analyst consensus of $-2.37 by +9.3%. The next INBX earnings date is expected around September 1, 2026.
Each quarter, investors track INBX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INBX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INBX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INBX earnings · 5 questionsInhibrx Biosciences, Inc.'s next earnings report is expected around September 1, 2026. INBX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INBX historically reports after market close (AMC).
INBX earnings datewhen is INBX earningsINBX next earnings datewhen does INBX report earningsINBX earnings calendar
▸ Source: FMP · Inhibrx Biosciences, Inc. SEC filings · US GAAP · Inhibrx Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026